Search results for:

amiodarone

amiodarone
  • Restricted Medications Cardiac Monitor (IV)
Drug Name Form Strength Non-Formulary Restricted TX Sub Notes
Cordarone SOLUTION, INTRAVENOUS 50 mg/mL vial      
Nexterone SOLUTION, INTRAVENOUS 150 mg/100 mL; 360 mg/200 mL      
Cordarone TABLET, ORAL 200 mg      
Display Antiarrhythmic Agents, Class II Antiarrhythmics, Class III Antiarrhythmics Class : 240404, 24040416, 24040420
Medication comments:
amiodarone should generally not be interrupted during procedures unless there is a specific physician order.
Per policy, these medications require cardiac and/or special monitoring.
(KEY: "Y" = may be given as described on chart. "N" = may NOT be given except in Rapid Response/Code Blue situations or as otherwise described in Exceptions section of Policy.
generic (Brand) / Notes CCU, OR, PACU, CCL, ED PCU 2N (Tele) 1N (Tele), 3N (Tele) Med/Surg (1N w/o Tele, 3N w/o Tele, 4N, 5N) BirthPlace SNF ICS OPS
amiodarone (Cordarone)
IV Push, IV Infusion		 Y Y Y N N N N N N
Medications Requiring Filters    
Medication Preparation Filter Administration Filter
amiodarone (Cordarone) Not required. Use a 0.22 micron inline filter.
Adult Extravasation Management
amiodarone (Cordarone)
Agent type: Non-Chemotherapeutic
Vesicant/Irritant: Vesicant
Local Care: Warm compress
Antidote: Hyaluronidase (may consider for refractory cases in addition to supportive measures)
Antidote link(s):
2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults.
Medication: amiodarone (Cordarone, Nexterone, Pacerone)
Criteria 1: Potentially inappropriate medication use in older adults. (Table 2)
Drug(s) amiodarone
Rationale Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial fibrillation; may be reasonable first-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control.
Recommendation Avoid as first-line therapy for atrial fibrillation unless the patient has heart failure or substantial left ventricular hypertrophy.
 Quality of evidence: High, Strength of Recommendation: Strong
Last updated: Nov. 2, 2025
UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556



This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.
Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved